Get the Stockscreener App
8.505
1.93%
0.235
Day One Biopharmaceuticals Inc stock is traded at $8.505, with a volume of 65,330.
It is up +1.93% in the last 24 hours and down -4.20% over the past month.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
See More
Previous Close:
$8.27
Open:
$8.28
24h Volume:
65,330
Relative Volume:
0.03
Market Cap:
$869.66M
Revenue:
$187.64M
Net Income/Loss:
$-95.00M
P/E Ratio:
-8.9526
EPS:
-0.95
Net Cash Flow:
$-69.02M
1W Performance:
+2.18%
1M Performance:
-4.20%
6M Performance:
+26.96%
1Y Performance:
-33.20%
1-Day Range:
$8.28
$8.47
1-Week Range:
$8.125
$8.671
52-Week Range:
$5.635
$13.53
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
Name
Day One Biopharmaceuticals Inc
Sector
Industry
Phone
650 484-0899
Address
1800 SIERRA POINT PARKWAY, SUITE 200, BRISBANE
Compare DAWN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DAWN
Day One Biopharmaceuticals Inc
|
8.47 | 849.13M | 187.64M | -95.00M | -69.02M | -0.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.94 | 115.62B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
747.99 | 79.10B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.72 | 52.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.76 | 51.72B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
199.67 | 42.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Oct-09-24 | Reiterated | Needham | Buy |
| Aug-01-24 | Upgrade | BofA Securities | Underperform → Buy |
| Apr-24-24 | Reiterated | Needham | Buy |
| Apr-25-23 | Downgrade | BofA Securities | Buy → Underperform |
| Feb-08-23 | Initiated | CapitalOne | Overweight |
| Feb-03-23 | Initiated | Oppenheimer | Perform |
| Dec-15-22 | Initiated | H.C. Wainwright | Buy |
| Dec-14-22 | Initiated | Needham | Buy |
| Dec-05-22 | Initiated | Goldman | Buy |
| Dec-01-22 | Initiated | BofA Securities | Buy |
View All
Day One Biopharmaceuticals Inc Stock (DAWN) Latest News
Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Day One Biopharma (DAWN) Announces Positive 3-Year Follow-up Results from Pivotal Phase 2 FIREFLY-1 Trial of OJEMDA (Tovorafenib) - Finviz
Day One Biopharma (DAWN) announces positive 3-year follow-up results from pivotal phase 2 FIREFLY-1 trial of OJEMDA (tovorafenib) - MSN
20 Stocks That Will Double in 2026 - Insider Monkey
Braidwell LP Has $14.18 Million Position in Day One Biopharmaceuticals, Inc. $DAWN - MarketBeat
Day One Biopharmaceuticals Reports Strong Q3 2025 Results - MSN
Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Down 4.9%What's Next? - MarketBeat
Why The Narrative Around Day One Biopharmaceuticals Is Shifting After The Mersana Acquisition - Yahoo Finance
Day One Biopharmaceuticals Expands with Mersana Acquisition - StocksToTrade
Day One Biopharmaceuticals (NASDAQ:DAWN) Sees Large Volume IncreaseTime to Buy? - MarketBeat
(DAWN) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Day One’s FIREFLY Trial Shows Promise in Pediatric Cancer Treatment - timothysykes.com
Day One Biopharmaceuticals (NASDAQ:DAWN) Nasdaq Futures Clinical-Stage Innovation - Kalkine Media
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
180,133 Shares in Day One Biopharmaceuticals, Inc. $DAWN Bought by Schroder Investment Management Group - MarketBeat
MRSN Stock Soars Over 200% Pre-Market After Day One Acquisition Deal - MSN
How buybacks impact Day One Biopharmaceuticals Inc. stock valueTrade Performance Summary & Verified High Yield Trade Plans - Newser
Day One to buy Mersana Therapeutics for $25/share upfront - MSN
Day One Biopharmaceuticals, Inc. $DAWN Shares Purchased by Geode Capital Management LLC - MarketBeat
Will Day One Biopharmaceuticals Inc. stock deliver shareholder valueJuly 2025 Patterns & Fast Exit and Entry Strategy Plans - Newser
Day One Biopharmaceuticals, Inc. $DAWN Shares Purchased by Virtus Investment Advisers LLC - MarketBeat
Franklin Resources Inc. Purchases 79,255 Shares of Day One Biopharmaceuticals, Inc. $DAWN - MarketBeat
What drives Day One Biopharmaceuticals Inc stock pricePrice Momentum Alerts & Investor Community Interactions - earlytimes.in
(DAWN) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
DAWN CEO moves Day One shares among Bender family trusts - Stock Titan
Day One Biopharmaceuticals (NASDAQ:DAWN) Trading 8% HigherStill a Buy? - MarketBeat
Day One Biopharmaceuticals stock maintains Buy rating at H.C. Wainwright By Investing.com - Investing.com UK
Day One Biopharmaceuticals' (DAWN) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
How Recent Developments Are Shaping the Day One Biopharma Investment Story - Yahoo Finance
HC Wainwright & Co. Reiterates Day One Biopharmaceuticals (DAWN) Buy Recommendation - Nasdaq
DAWN: HC Wainwright & Co. Reaffirms Buy Rating with $25 Target | - GuruFocus
Buy Rating Affirmed for Day One Biopharmaceuticals: Promising FIREFLY-1 Trial Results and Ojemda’s Market Potential - TipRanks
Day One Biopharmaceuticals Announces Three-Year Results from FIREFLY-1 Trial - TradingView
Day One Announces Three Year Follow-Up Data From OJEMDA™ (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting - The Manila Times
[8-K] Day One Biopharmaceuticals, Inc. Reports Material Event | DAWN SEC FilingForm 8-K - Stock Titan
Day One Announces Three Year Follow-Up Data From OJEMDA™ - GlobeNewswire
Will Hindalco Industries Limited Stock Benefit From Industry Trends in YEARBearish Engulfing Patterns & Minimize Portfolio Damage with Warnings - earlytimes.in
Is Day One Biopharmaceuticals Inc a good long term investmentRisk Adjusted Returns & High Profit Market Tips - earlytimes.in
Day One Biopharmaceuticals unveils promising Phase 2 trial data - Traders Union
Will Day One Biopharmaceuticals Inc. stock maintain momentum in 2025Trade Analysis Report & Verified Chart Pattern Trade Signals - newser.com
Can Day One Biopharmaceuticals Inc. stock maintain growth trajectoryWeekly Stock Summary & Technical Confirmation Trade Alerts - newser.com
Wall Street Analysts Believe Day One Biopharmaceuticals (DAWN) Could Rally 161.36%: Here's is How to Trade - MSN
Can Day One Biopharmaceuticals Inc. stock deliver consistent earnings growthJuly 2025 Breakouts & Real-Time Market Trend Scan - newser.com
Will Day One Biopharmaceuticals Inc. stock recover faster than peersAnalyst Upgrade & Safe Entry Zone Tips - newser.com
Day One Biopharmaceuticals, Inc.Common Stock (NQ: DAWN - Markets Financial Content
Day one biopharma gen counsel sells $38k in shares By Investing.com - Investing.com South Africa
Can Day One Biopharmaceuticals Inc. rally from current levelsQuarterly Trade Review & Free Low Drawdown Momentum Trade Ideas - newser.com
Key resistance and support levels for Day One Biopharmaceuticals Inc.Index Update & Safe Swing Trade Setup Alerts - newser.com
Day One Biopharmaceuticals Inc. stock volume spike explainedTrade Signal Summary & Weekly High Conviction Trade Ideas - newser.com
Day One Biopharmaceuticals Inc Stock (DAWN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Day One Biopharmaceuticals Inc Stock (DAWN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| York Charles N II | COO and CFO |
Nov 17 '25 |
Sale |
8.91 |
4,062 |
36,212 |
294,715 |
| Merendino Lauren | Chief Commercial Officer |
Nov 17 '25 |
Sale |
8.91 |
3,726 |
33,216 |
50,809 |
| Bender Jeremy | CHIEF EXECUTIVE OFFICER |
Nov 17 '25 |
Sale |
8.91 |
15,894 |
141,690 |
177,165 |
0.42%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):